Literature DB >> 15744624

Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas.

M Nakamura1, F Roser, J Michel, C Jacobs, M Samii.   

Abstract

OBJECTIVE: Intracranial meningiomas are mostly considered to be slow growing tumors. However, only a few previous reports provide information on the growth rate of these tumors. The aim of this study was to determine the growth rates of intracranial meningiomas after subtotal resection, analysing their relation to radiological appearance and histological features. Results are compared with our previous analysis of growth rates in incidental meningiomas .
METHODS: The hospital charts, follow up records and imaging studies were reviewed in 36 patients with subtotally resected intracranial meningiomas. The tumor growth rates were determined by calculating the absolute and relative growth rates and the tumor volume doubling times.
RESULTS: In the group of 33 patients with histologically verified grade 1 meningiomas, the mean absolute growth rate was 1.51 cm (3)/year, the median relative growth rate and tumor doubling time was 14.18 %/year and 5.228 years. In young patients annual relative growth rates were significantly higher. The median annual relative growth rate of meningiomas with calcification was significantly lower than in tumors without calcification. Also tumors with hypo- or isointense T (2)-signals on MRI revealed a lower growth rate. There was no significant difference between males and females. Histological studies revealed 22 meningiomas of a meningotheliomatous subtype, 8 fibrous and 3 psammomatous meningiomas. The comparison of growth rates between these subtypes did not show any significant differences. In atypical meningiomas (WHO grade 2), absolute and relative growth rates were significantly higher and tumor doubling times shorter.
CONCLUSION: The majority of intracranial meningiomas are slow growing tumors, although the growth rates may vary widely even among benign grade 1 meningiomas. In meningiomas after subtotal surgical resection, the age of the patients seems to present a predictive factor for tumor growth in analogy to our previous observation in incidental meningiomas. Significantly higher relative growth rates were detected in younger patients. Gender does not seem to play a major role as a predictive factor. Radiological features such as calcification or T (2)-signal intensity may provide additional information to predict the growth potential of meningiomas. Close clinical and radiological observation should be performed in young patients harboring tumors with absence of calcification or high T (2)-signal intensities due to the higher growth potential in this patient group.

Entities:  

Mesh:

Year:  2005        PMID: 15744624     DOI: 10.1055/s-2004-836225

Source DB:  PubMed          Journal:  Zentralbl Neurochir        ISSN: 0044-4251


  10 in total

1.  Growth curve analysis of asymptomatic and symptomatic meningiomas.

Authors:  Satoshi Nakasu; Yoko Nakasu; Tadateru Fukami; Junya Jito; Kazuhiko Nozaki
Journal:  J Neurooncol       Date:  2010-08-05       Impact factor: 4.130

2.  Volumetric growth rate of incidental asymptomatic meningiomas: a single-center prospective cohort study.

Authors:  Pedro David Delgado-López; Antonio Montalvo-Afonso; Javier Martín-Alonso; Vicente Martín-Velasco; José Manuel Castilla-Díez; Ana María Galacho-Harriero; Sara Ortega-Cubero; Antonio Sánchez-Rodríguez; Antonio Rodríguez-Salazar
Journal:  Acta Neurochir (Wien)       Date:  2021-03-22       Impact factor: 2.216

3.  Consensus core clinical data elements for meningiomas (v2021.1).

Authors:  Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

4.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 5.  Advances in meningioma therapy.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

Review 6.  Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review.

Authors:  Daniel M Fountain; Wai Cheong Soon; Tomasz Matys; Mathew R Guilfoyle; Ramez Kirollos; Thomas Santarius
Journal:  Acta Neurochir (Wien)       Date:  2017-01-18       Impact factor: 2.216

7.  Preoperative Prediction of Intracranial Meningioma Grade Using Conventional CT and MRI.

Authors:  Toshiyuki Amano; Akira Nakamizo; Hideki Murata; Yuichiro Miyamatsu; Fumihito Mugita; Koji Yamashita; Tomoyuki Noguchi; Shinji Nagata
Journal:  Cureus       Date:  2022-01-25

Review 8.  Molecular determinants of outcomes in meningiomas.

Authors:  John Lynes; Gabriel Flores-Milan; Sebastian Rubino; John Arrington; Robert Macaulay; James K C Liu; Andre Beer-Furlan; Nam D Tran; Michael A Vogelbaum; Arnold B Etame
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

9.  Is Contrast Medium Really Needed for Follow-up MRI of Untreated Intracranial Meningiomas?

Authors:  J Boto; R Guatta; A Fitsiori; J Hofmeister; T R Meling; M I Vargas
Journal:  AJNR Am J Neuroradiol       Date:  2021-06-11       Impact factor: 4.966

Review 10.  Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

Authors:  Riccardo Laudicella; Domenico Albano; Salvatore Annunziata; Diletta Calabrò; Giovanni Argiroffi; Elisabetta Abenavoli; Flavia Linguanti; Domenico Albano; Antonio Vento; Antonio Bruno; Pierpaolo Alongi; Matteo Bauckneht
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.